title: Carfilzomib in multiple myeloma: gold, silver, or bronze?
abstract: In this issue of Blood, Siegel and colleagues report that the next-generation proteasome inhibitor carfilzomib, when administered as a single agent, can produce meaningful disease control in heavily pretreated patients with relapsed/refractory multiple myeloma.(1)
authors.affiliation: Princess Margaret Hospital, Canada.
authors.forename: Donna E
authors.initials: DE
authors.lastname: Reece
mesh_terms: D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use*; D016879:Salvage Therapy
chemical_list: D009842:Oligopeptides; C524865:carfilzomib